

신경교종에서 뇌동맥내 Carboplatin주입후 발생한 안구 합병증

- 3례보고 -

김주한 · 이장보 · 정용구 · 박정율 · 이훈갑 · 서중근

=Abstract=

Ocular Complications after Injection of Intra-arterial Carboplatin in Gliomas - Report of Three Cases -

Joo-Han Kim, M.D., Jang-Bo Lee, MD., Yong-Gu Chung, MD.,
Jung-Yul Park, MD., Hun-Kap Lee, MD., Jung-Keun Suh, MD.

Department of Neurosurgery, College of Medicine, Korea University, Seoul, Korea

Carboplatin intra-arterial chemotherapy(IAC) has an advantage of increased uptake during the first passage of the drugs through tumor capillaries. Although not common, this type of therapy is known to cause neurological complications, myelosuppression, and ototoxicity. However, the incidence of ocular toxicity is reported to be rare. Eleven of our patients with glioma(Grade II Astrocytoma : 3, Grade III Astrocytoma : 1, Grade IV Astrocytoma : 5, Gliofibroma : 1, Oligodendroglioma : 1) underwent IAC regimen with carboplatin(300mg/m²) which were administrated after blood-brain barrier disruption. Of there, 3 patients had ocular complications after supra-ophthalmic IAC injection of carboplatin but fully recovered following steroid therapy. Although our results from IAC seem to be favorable for these patients, we suggest that its complications, such as ocular toxicity, need to be carefully considered prior to treatment.

KEY WORDS : Intra-arterial chemotherapy · Carboplatin · Ocular complications.

서론

tin

, carboplatin

3

piro⁶⁾

mustard

. 1952 Sha-

증례보고(3례)

, 1977 Fenstermacher¹⁾

BCNU

carboplatin

20% mannitol 100ml solumedrol

BCNU

125mg

4)7)

, 1982 St-

. carboplatin(300

ewart⁹⁾
carboplatin

carboplatin

mg/m²) 5%

30

4

carbopla-

Carboplatin

Table 3. Toxicity and response of patients with gliomas after combined intraarterial and systemic chemotherapy

Patient	Tumor type	Artery infused	No. courses of intra-arterial chemo-therapy	Toxicity			Response ^b	Comments
				Neurological	Oculara	Other		
1	Gliofibroma	Carotid	5		1+ pain	Myelosuppression	F	#1 ACNU 2mg/kg/IV, vincristine 1mg/IV, procarbazine 100mg/PO*14days #2 tamoxifen 40-60-80mg/PO #*c1 - 5 carboplatin 430mg/IAC
2	Grade IV ASCY	Carotid	1				ED	#*1 carboplatin 465mg/IAC #*1 - 3 carboplatin 513mg/IAC
3	Oligodendrogioma	Carotid	4	Dizziness	2+ pain visual dimness conjunctival injection & swelling (POD #3) Retinochoroiditis? Toxic retinopathy?	Myelosuppression, 2+ headache, nausea & vomiting	R	#*4 carboplatin 480mg/IAC
4	Grade IV ASCY	Carotid	3		4+ pain Visual dimness conjunctival injection & Swelling (#2 IACHemo)	motor weakness (#3 IACHemo) Cb infarction	R	#*1 carboplatin 450mg/IAC
5	Grade IV ASCY	Carotid	1				F	#1 ACNU 2mg/kg/IV vincristine 1mg/IV procarbazine 100mg/PO*14days #2 - 3 tamoxifen 100-120mg/PO
6	Grade IV ASCY	Carotid	1				F	#*1 carboplatin 500mg/IAC #1 tamoxifen 120mg/PO
7	Grade III ASCY	Carotid	4				R	#*1 carboplatin 576mg/IAC #*2 - 4 carboplatin 550mg/IAC
8	Grade II ASCY	Carotid	5				R	#1 - 2 Brachytherapy #1 ACNU 2mg/kg/IV vincristine 1mg/IV procarbazine 100mg/PO*14days #*1 - 2 carboplatin 520mg/IAC #*3 - 5 carboplatin 540mg/IAC
9	Grade IV ASCY	Carotid	4				R	#1 Systemic CTx #*1 - 4 carboplatin 550mg/IAC
10	Grade II ASCY	Carotid	1		4+ pain visual dimness scleral & conjunctival injection & swelling severe retinal detachment		R	#*1 carboplatin 530mg/IAC
11	Grade II ASCY	Carotid	2				R	#1 ACNU 2mg/kg/IV #*1 - 2 carboplatin 510mg/IAC

a : Pain was periorbital location during and post IAC, rating of ocular and other toxicity, 0, none, 1+, mild, 2+, moderate, 3+, severe, 4+, extremely severe, a range is given if degree of toxicity varied from one to another.

b : R : response, S, stable, F, fail, ED, early death 3weeks after treatment, NE, not evaluated

c * : IAC treatment regimen, carboplatin 300mg/m²

가 carboplatin 가
4 . 11 carbo- 300mg/m²
platin 1 , 3 , carboplatin
9.7% Carboplatin

Fujiwara ³⁾
 boplatin
 carboplatin
 . Tfayli ¹⁰⁾
 가
 가
 carboplatin
 가 carboplatin
 . carbo-
 ,
 carbo-
 platin
 platin
 가
 11)
 .
 결론
 가 가
 carboplatin
 가
 carboplatin
 가
 .
 • : 2000 5 12
 • : 2001 4 14
 • :
 427 - 707 516
 : 032) 412 - 5053, : 032) 412 - 5054

References

1) Fenstermacher JD, Cowles AL : *Theoretic limitations at intracarotid infusions in brain tumor chemotherapy. Cancer Treat Rep* 61 : 519-526, 1977
 2) Follzou JY, Fauchon F, Chiras J : *Intraarterial infusion of*

carboplatin in the treatment of malignant glioma ; a phase II study. Neoplasma 36 : 349-352, 1989
 3) Fujiwara T, Matsumoto Y., Honma Y, Kuyama H, Nagao S, Ohkawa M : *A comparison of intraarterial carboplatin and ACNU for the treatment of gliomas. Surg Neurol* 44 : 145-150, 1995
 4) Greenberg HS, Ensminger WD, Chandler WF, Layton PB, Junck L, Vine AK : *Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg* 61 : 423-429, 1984
 5) Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Hilojevic L, Djuric L, et al : *Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma ; a phase II study. J Clin Oncol* 10 : 1074-1077, 1992
 6) Shapiro WR, Ausman JI : *The chemotherapy of brain tumors ; a clinical and experimental review. in Plum F, McDowell FH(eds) : Recent Advances in Neurology. Philadelphia, 1969, pp149-235*
 7) Shapiro WR, Green SB, Burger PC, Selker RG, VonGilder JC, Robertson JT, et al : *A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg* 76 : 772-781, 1992
 8) Stewart DJ, Belanger JM, Grahovac Z, Curuvija S, Gionet LR, Aitken SE, et al : *Phase I study of intracarotid administration of carboplatin. Neurosurg* 30 : 512-517, 1992
 9) Stewart DJ, Leavens M, Maor M, Fevin L, Luna M, Bonura J, et al : *Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res* 42 : 2474-2479, 1982
 10) Tfayli A, Hentschel P, Madajewicz S : *Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol* 42 : 73-77, 1999
 11) Urba S, Forastiere AA : *Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer. Cancer* 62 (10) : 2094-2097, 2097 1988
 12) Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman H, et al : *Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurg* 37 : 17-27, 1995